Phase II trial evaluating the combination of eribulin (E)+ bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study

Authors :: P. Ardisson
M. Leheurteur
A-C. Hardy-Bessard
A. Mercier-Blas
Jérôme Dauba
A. Melis
A. Marti
A-M. Savoye
N. Barbier
E. Guardiola
Jérôme Meunier
Fabien Brocard
J. Grenier
N. Gane
R. Despax
Benoit You
J. Martin-Babau
Philippe Follana
C. Segura-Djezzar
Alain Lortholary
Source :: Annals of Oncology. 27:vi72
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: Oncology
medicine.medical_specialty
Group study
Bevacizumab
business.industry
HER2 negative
Hematology
medicine.disease
chemistry.chemical_compound
Breast cancer
chemistry
Internal medicine
Medicine
In patient
First line chemotherapy
business
Eribulin
medicine.drug

Full Text Access

Tools